201 related articles for article (PubMed ID: 36068210)
1. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.
Islam F; Marshe VS; Magarbeh L; Frey BN; Milev RV; Soares CN; Parikh SV; Placenza F; Strother SC; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
Transl Psychiatry; 2022 Sep; 12(1):366. PubMed ID: 36068210
[TBL] [Abstract][Full Text] [Related]
2. Influence of
Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
[TBL] [Abstract][Full Text] [Related]
3. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
Waade RB; Hermann M; Moe HL; Molden E
Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
Naujokaitis D; Asmoniene V; Kadusevicius E
Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
[TBL] [Abstract][Full Text] [Related]
6. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
Hendset M; Hermann M; Lunde H; Refsum H; Molden E
Eur J Clin Pharmacol; 2007 Dec; 63(12):1147-51. PubMed ID: 17828532
[TBL] [Abstract][Full Text] [Related]
7. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
Kringen MK; Bråten LS; Haslemo T; Molden E
J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.
Smith RL; Molden E; Bernard JP
Br J Clin Pharmacol; 2023 Jul; 89(7):2246-2253. PubMed ID: 36851891
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.
Honeycutt DC; Blom TJ; Ramsey LB; Strawn JR; Bruns KM; Welge JA; Patino LR; Singh MK; DelBello MP
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):42-51. PubMed ID: 38377518
[No Abstract] [Full Text] [Related]
11. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
[TBL] [Abstract][Full Text] [Related]
12. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Chakrabarty T; McInerney SJ; Torres IJ; Frey BN; Milev RV; Müller DJ; Rotzinger S; Kennedy SH; Lam RW;
CNS Drugs; 2021 Mar; 35(3):291-304. PubMed ID: 33683582
[TBL] [Abstract][Full Text] [Related]
13. Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals.
Tveit K; Hermann M; Nilsen RM; Wallerstedt SM; Rongve A; Molden E; Hole K
Eur J Clin Pharmacol; 2024 Mar; 80(3):435-444. PubMed ID: 38197945
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
[TBL] [Abstract][Full Text] [Related]
15. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese.
He L; Chen S; Li J; Xie X; Huang L; Kuang Y; Xu K; Huang W; Zhao Y; Yang G; Guo C
Clin Exp Pharmacol Physiol; 2020 Oct; 47(10):1659-1663. PubMed ID: 32469422
[TBL] [Abstract][Full Text] [Related]
16. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
Kuhlmann JB; Wensing G; Kuhlmann J
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
[TBL] [Abstract][Full Text] [Related]
17. Frequencies of
Scherf-Clavel M; Weber H; Unterecker S; Müller DJ; Deckert J
World J Biol Psychiatry; 2024 Apr; 25(4):214-221. PubMed ID: 38493365
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.
Hole K; Haslemo T; Molden E
Ther Drug Monit; 2023 Oct; 45(5):683-688. PubMed ID: 37012633
[TBL] [Abstract][Full Text] [Related]
19. Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study.
Calabrò M; Fabbri C; Kasper S; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; De Ronchi D; Serretti A; Crisafulli C
Eur Neuropsychopharmacol; 2022 Mar; 56():100-111. PubMed ID: 35152032
[TBL] [Abstract][Full Text] [Related]
20. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.
Fabbri C; Tansey KE; Perlis RH; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Breen G; Curtis C; Lee SH; Newhouse S; Patel H; O'Donovan M; Lewis G; Jenkins G; Weinshilboum RM; Farmer A; Aitchison KJ; Craig I; McGuffin P; Schruers K; Biernacka JM; Uher R; Lewis CM
Eur Neuropsychopharmacol; 2018 Aug; 28(8):945-954. PubMed ID: 30135031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]